Cancer Clinical Trials Bounce Back After Significant COVID-19 Disruption
Deborah Doroshow, MD, PhD, discusses her study at The Tisch Cancer Institute with The Dana-Farber Cancer Institute about how the COVID-19 pandemic caused substantial disruption to clinical trials for cancer treatment and care.